Dacemazine

Dacemazine (INN, also known as Ahistan and Histantine)[1] is a phenothiazine derivative which acts as a histamine antagonist at the H₁ subtype. First described in 1951, it was never marketed as a drug on its own, although a combination of dacemazine and di-tert-butylnaphthalenesulfonate was sold as an antispasmodic and antitussive under the trade name Codopectyl.[1] It was also assessed as a possible anticancer drug.[2]

Dacemazine

Clinical data
ATC code	none
Identifiers
IUPAC name 2-dimethylamino-1-phenothiazin-10-ylethanone
CAS Number	518-61-6^N
PubChem CID	68846
ChemSpider	62079^Y
UNII	88D34UY0QI
ChEMBL	ChEMBL2107547^N
CompTox Dashboard (EPA)	DTXSID70199733
Chemical and physical data
Formula	C16H16N2OS
Molar mass	284.38 g·mol^−1
3D model (JSmol)	Interactive image
SMILES O=C(N1c3c(Sc2c1cccc2)cccc3)CN(C)C
InChI InChI=1S/C16H16N2OS/c1-17(2)11-16(19)18-12-7-3-5-9-14(12)20-15-10-6-4-8-13(15)18/h3-10H,11H2,1-2H3^Y Key:HKUCYAHWPVLPFN-UHFFFAOYSA-N^Y
^NY (what is this?)  (verify)

References

1. Triggle DJ, Ganellin CR, MacDonald F (1996). Dictionary of Pharmacological Agents. 1. Boca Raton: Chapman & Hall/CRC. p. 711. ISBN 0-412-46630-9. Retrieved on August 2, 2008 through Google Book Search.
2. Karolyhazy G, Havas I, Jansco G, Kapas L, Sellei C (August 1952). "[The anticarcinogenic effect of dimethylaminoacetyl-phentiazide (ahistan)]". Kiserletes Orvostudomany (in Romanian). 4 (4): 260–2. PMID 13023855.